製品番号: HY-76200

ボリコナゾール

(別名: Voriconazole; UK-109496)

11 Cited Publications

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes. Voriconazole can penetrate the blood brain barrier (BBB).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.45%
CAS 番号: 137234-62-9
分子式: C₁₆H₁₄F₃N₅O
分子量:349.31

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Voriconazole 構造式

CAS 番号: 137234-62-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (11)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>30 μM Compound: VOR	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
CHO	IC₅₀	>40 μM Compound: 3	Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay Inhibition of human ERG expressed in CHO cells by whole-cell patch clamp assay	[PMID: 24564525]
CHO	IC₅₀	414.2 μM Compound: voriconazole	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
Hepatocyte	IC₅₀	13 μM Compound: Voriconazole	Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	[PMID: 24948565]
MCF7	IC₅₀	>30 μM Compound: VOR	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]
MRC5	IC₅₀	40 μg/mL Compound: VOR	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 26867487]
MRC5	IC₅₀	40 μg/mL Compound: Voriconazole	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 26586600]
THLE-2	IC₅₀	>30 μM Compound: VOR	Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay Cytotoxicity against human THLE-2 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay	[PMID: 34388384]

体外実験

Voriconazole has great activity against S. apiospermum and C. neoformans with the MICs of 0.5 μg/mL and 0.125-0.25 μg/mL, respectively^[1].
Voriconazole inhibits the cytochrome P450 (CYP)-dependent enzyme 14-alpha-sterol demethylase, thereby disrupting the cell membrane and halting fungal growth^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Voriconazole (5-20 mg/kg; p.o. for 21 days) prolongs survival in a dose-dependent fashion. Voriconazole (40 mg/kg/day) decreases the fungal burden in the lungs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male specific-pathogen-free BALB/cByJ mice^[3]
Dosage:

1, 5, 20 mg/kg/day
Administration:

P.o. once daily for 21 days
Result:

Improved survival in a dose-response fashion, with median survival times (MSTs) of 21, 28, and 35 days with doses of 1, 5, and 20 mg/kg, respectively.

化学情報

CAS 番号 137234-62-9
性状 Solid
分子量 349.31
分子式 C₁₆H₁₄F₃N₅O
Color White to off-white
SMILES

O[C@@](CN1N=CN=C1)(C2=CC=C(F)C=C2F)[C@H](C3=NC=NC=C3F)C
別名

Voriconazole; UK-109496
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (11)

All OthersIn Vivo Efficacy StudyMicrobiological AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Transl Res

A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1. [Abstract]

2022 Sep:247:39-57. PMID: 35452875
Front Cell Infect Microbiol

Caenorhabditis elegans- Based Aspergillus fumigatus Infection Model for Evaluating Pathogenicity and Drug Efficacy. [Abstract]

2020 Jun 26:10:320. PMID: 32670897

Voriconazole purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26:10:320. [Abstract]

Kaplan-Meier survival plots of C. elegans infected by KU80Δ in the presence of antifungal drugs. The glp-4(bn2); sek-1(km4) worms were pre-infected with KU80Δ for 8 h then transferred into liquid killing media containing different concentrations of Voriconazole (0-1.5 μg/mL).

Voriconazole purchased from MedChemExpress. Usage Cited in: Front Cell Infect Microbiol. 2020 Jun 26:10:320. [Abstract]

Effect of antifungal treatment on Af293-dsRed infection to glp-4(bn2); sek-1(km4) worms. Images were taken under DIC and TRITC channels from DMSO treatment by 24 h, 1.5 μg/ml AmB treatment by 48 h, 2 μg/ml ItrZ treatment by 72 h and 0.5 μg/ml Voriconazole treatment by 72 h. Scale bar is 200 μm.
BMC Microbiol

In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus. [Abstract]

2025 Nov 5;25(1):715. PMID: 41194018

Voriconazole purchased from MedChemExpress. Usage Cited in: BMC Microbiol. 2025 Nov 5;25(1):715. [Abstract]

Interaction profile of REV combined with ITR, Voriconazole and POS against Aspergillus spp.
Microchem J

2026 Mar 27.
Microbiol Spectr

Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistant Candida tropicalis. [Abstract]

2025 May 6;13(5):e0318524. PMID: 40162832

Voriconazole purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2025 May 6;13(5):e0318524. [Abstract]

MIC values of antifungal drugs (Voriconazole) against CT27.
Drug Metab Dispos

Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. [Abstract]

2025 Nov;53(11):100168. PMID: 41124962
Med Mycol

Lonafarnib synergizes with azoles against Aspergillus spp. and Exophiala spp. [Abstract]

2018 Jun 1;56(4):452-457. PMID: 29420769
Infect Drug Resist

Correlation Between Drug Resistance and Virulence of Candida Isolates from Patients with Candidiasis. [Abstract]

2022 Dec 15:15:7459-7473. PMID: 36544991
J Mycol Med

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. [Abstract]

2022 Mar;32(1):101227. PMID: 34800920
Laryngoscope Investig Otolaryngol

Clinical and mycological investigations of post-COVID-19 acute invasive fungal sinusitis. [Abstract]

2022 Oct 28;7(6):1780-1789. PMID: 36544940
bioRxiv

Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilization. [Abstract]

2025 Oct 14:2025.10.13.682145. PMID: 41279189

Voriconazole purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]

Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated with Voriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays.

Voriconazole purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]

Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated with Voriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays. Numbers of CFU-C in peripheral blood of C57BL/6J mice after the indicated treatments.

Voriconazole purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 14:2025.10.13.682145. [Abstract]

Experimental design for HSPC mobilization. Wild-type C57BL/6J or Townes SCD mice were treated withVvoriconazole (50 mg/kg/day, iv) or vehicle intravenously daily for four days, followed by AMD3100 or vehicle one hour before peripheral blood collection for CFU assays. Numbers of CFU-gmEM (C) in peripheral blood of C57BL/6J mice after the indicated treatments.

溶剤 & 溶解度

体外:

DMSO : ≥ 50 mg/mL (143.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 0.17 mg/mL (0.49 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8628 mL

14.3139 mL

28.6279 mL

5 mM

0.5726 mL

2.8628 mL

5.7256 mL

10 mM

0.2863 mL

1.4314 mL

2.8628 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Nickie D Greer, et al. Voriconazole: the newest triazole antifungal agent.Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8. [Content Brief]

[2]. Michael E Henry, et al. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrob Agents Chemother. 2013 Nov;57(11):5271-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8628 mL	14.3139 mL	28.6279 mL	71.5697 mL
	5 mM	0.5726 mL	2.8628 mL	5.7256 mL	14.3139 mL
	10 mM	0.2863 mL	1.4314 mL	2.8628 mL	7.1570 mL
	15 mM	0.1909 mL	0.9543 mL	1.9085 mL	4.7713 mL
	20 mM	0.1431 mL	0.7157 mL	1.4314 mL	3.5785 mL
	25 mM	0.1145 mL	0.5726 mL	1.1451 mL	2.8628 mL
	30 mM	0.0954 mL	0.4771 mL	0.9543 mL	2.3857 mL
	40 mM	0.0716 mL	0.3578 mL	0.7157 mL	1.7892 mL
	50 mM	0.0573 mL	0.2863 mL	0.5726 mL	1.4314 mL
	60 mM	0.0477 mL	0.2386 mL	0.4771 mL	1.1928 mL
	80 mM	0.0358 mL	0.1789 mL	0.3578 mL	0.8946 mL
	100 mM	0.0286 mL	0.1431 mL	0.2863 mL	0.7157 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Voriconazole

11 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ボリコナゾール

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

MedChemExpress（MCE）の使用を引用している文献 Voriconazole

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ボリコナゾール

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

MedChemExpress（MCE）の使用を引用している文献 Voriconazole

生物活性

化学情報

Publications (11)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Voriconazole 関連分類

HY-76200 関連分類